Business Description
MyMD Pharmaceuticals Inc
NAICS : 541713
SIC : 2833
ISIN : US62856X1028
Share Class Description:
FRA:DQS0: Ordinary SharesDescription
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 48.19 | |||||
Equity-to-Asset | 0.69 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -16.6 | |||||
3-Year EPS without NRI Growth Rate | -19.4 | |||||
3-Year FCF Growth Rate | -30.7 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 28.46 | |||||
14-Day RSI | 31.61 | |||||
6-1 Month Momentum % | -67.19 | |||||
12-1 Month Momentum % | -95.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.62 | |||||
Quick Ratio | 0.62 | |||||
Cash Ratio | 0.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.7 | |||||
Shareholder Yield % | 1.53 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -98.7 | |||||
ROA % | -56.98 | |||||
ROIC % | -133.27 | |||||
ROC (Joel Greenblatt) % | -21381.48 | |||||
ROCE % | -97.16 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.48 | |||||
EV-to-EBIT | -0.2 | |||||
EV-to-EBITDA | -0.2 | |||||
EV-to-FCF | -0.32 | |||||
Earnings Yield (Greenblatt) % | -493.25 | |||||
FCF Yield % | -214.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MyMD Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -8.775 | ||
Beta | 2.32 | ||
Volatility % | 60.06 | ||
14-Day RSI | 31.61 | ||
14-Day ATR (€) | 0.000449 | ||
20-Day SMA (€) | 1.89 | ||
12-1 Month Momentum % | -95.91 | ||
52-Week Range (€) | 1.89 - 53.1 | ||
Shares Outstanding (Mil) | 2.31 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
MyMD Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
MyMD Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
MyMD Pharmaceuticals Inc Frequently Asked Questions
What is MyMD Pharmaceuticals Inc(FRA:DQS0)'s stock price today?
The current price of FRA:DQS0 is €1.89. The 52 week high of FRA:DQS0 is €53.10 and 52 week low is €1.89.
When is next earnings date of MyMD Pharmaceuticals Inc(FRA:DQS0)?
The next earnings date of MyMD Pharmaceuticals Inc(FRA:DQS0) is 2024-08-14 Est..
Does MyMD Pharmaceuticals Inc(FRA:DQS0) pay dividends? If so, how much?
MyMD Pharmaceuticals Inc(FRA:DQS0) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |